Estimated cost of treating myasthenia gravis in an insured U.S. population

Abstract

The estimated annual health plan paid costs for treating MG were $15,675. Home health services represented 23% of MG patient costs, largely driven by IVIg administration.

Burden of illness in patients with treatment refractory myasthenia gravis

“…Over half of refractory patients required an inpatient stay, compared with less than one‐fourth of nonrefractory patients. In a study of an MG population as a whole by Guptill et al, 12.4% of MG patients required an inpatient admission . The lower rates of inpatient hospitalizations reported in the Guptill study, comparatively, may be related to their exclusion of patients with conditions typically requiring high healthcare utilization (i.e., human immunodeficiency virus/acquired immunodeficiency virus, organ transplant, renal failure, end‐stage renal disease, and malignant cancer).…”

Health plan paid cost of epilepsy in 2009 in the U.S.

“…Propensity score matching has been used by others to determine disease costs for other conditions like Parkinson's disease [22], myasthenia gravis [23], nosocomial pneumonia [24], clostridium infection [25], and gout [26]. Hence, we determined that the matched-pair design was the best alternative to using a completely randomized design (CRD) to attain our stated objective.…”

Mechanisms of Autoantibody-Induced Pathology

“…Therefore, the use of these drugs is often hampered by delayed clinical response. Plasmapheresis and IVIG are used for acute severe exacerbations in generalized MG. For a chronic disease like MG, the current treatment has a high cost (203), as most patients during the long-term treatment suffer several undesirable side effects (204). A distinct subset of patients often referred to as having refractory MG, do not respond well to current treatments (205).…”